Open access
SRC Activation Drives Acquired Pemetrexed Resistance in Non‐Small Cell Lung Cancer and Is Targetable by Dasatinib
Jeongmin Seo
Kui-Jin Kim
Se Hyun Kim
J. Sung
Sung-Hyun Hwang
Woochan Park
M. Kang
E. Jung
Sang-A Kim
K. J. Suh
Ji-Yun Lee
Ji-Won Kim
J. Lee
Jin Won Kim
Y. Kim
Keun-Wook Lee
J. Kim
S.-M. Bang
J. Kwon
J. Lee
Medicine
Abstract
Pemetrexed, a standard antifolate chemotherapy for non‐squamous non‐small cell lung cancer (NSCLC), is often limited by acquired resistance. We investigated whether SRC kinase mediates pemetrexed resistance and whether SRC inhibition can suppress survival signaling in pemetrexed‐resistant NSCLC cells.